![Aaron D. Fox](https://assets.montefioreeinstein.org/profiles/images/11501-aaron-fox.jpg)
Aaron D. Fox, M.D., M.S.
- Professor, Department of Medicine (General Internal Medicine)
Area of research
- Opioid use disorder treatment; Harm Reduction; HIV prevention; Incarceration and Health.
Phone
Location
- Montefiore Medical Center 3330 Kossuth Avenue 4 Bronx, NY 10467
Research Profiles
Professional Interests
Dr. Fox is a Professor of Medicine in the Division of General Internal Medicine at Albert Einstein College of Medicine/Montefiore Medical Center. He is board-certified in Internal Medicine and Addiction Medicine. Dr. Fox is the Director of the Bronx Transitions Clinic, which provides a medical home to persons with chronic health conditions who were recently released from incarceration. His expertise is in opioid use disorder and the related problems of HIV, incarceration, and chronic pain. Dr. Fox has been the principal investigator on clinical trials of buprenorphine treatment at syringe services programs, low-dose buprenorphine treatment initiation for hospitalized patients with chronic pain, and a group medical visit model for buprenorphine treatment. His studies have been funded by the National Institute on Drug Abuse, the New York State AIDS Institute, the Center for Medicare and Medicaid Innovation, and the Society of General Internal Medicine among other funders.
Dr. Fox graduated from the Albert Einstein College of Medicine in 2004, completed residency training at Montefiore in the Primary Care/Social Internal Medicine Residency Program in 2007, also serving as Chief Resident in 2008, and he received a Masters Degree in Clinical Research Methods from Einstein in 2012. In addition to providing clinical care and conducting research, Dr. Fox also teaches medical students, residents, and fellows on addiction medicine, incarceration and health, physician advocacy, and research skills. Dr. Fox is the President of the New York Society of Addiction Medicine.
Selected Publications
Selected Publications. Full Bibliography here
Fox AD, Navos Behrends C, Perez-Correa A, Riback L, Ohlendorf E, Ghiroli M, López-Castro T. High interest in injectable opioid agonist treatment with hydromorphone among NYC syringe service program participants. Subst Use Addctn. 2024 Jan;45(1):44-53.
Jakubowski A, Fox AD. Defining low-threshold buprenorphine treatment. J Addict Med. 2020 Mar/Apr;14(2):95-98.
Joudrey PJ, Khan MR, Wang EA, Scheidell JD, Edelman EJ, McInnes DK, Fox AD. A conceptual model for understanding post-release opioid-related overdose risk. Addict Sci Clin Pract. 2019 Apr 15;14(1):17.
Howell BA, Earnshaw VA, Garcia M, Taylor A, Martin K, Fox A. The stigma of criminal justice involvement and health: a conceptual framework. J Urban Health. 2022 Feb;99(1):92-101.
Hayes BT, Favaro J, Davis CS, Gonsalves GS, Beletsky L, Vlahov D, Heimer R, Fox AD. Harm Reduction, By Mail: the Next Step in Promoting the Health of People Who Use Drugs. J Urban Health. 2021; 98(4):532-537.
Hagan B, Wang EA, Aminawung JA, Albizu-Garcia C, Zaller N, Nyamu S, Shavit S, Deluca J, Fox AD. History of solitary confinement is associated with Post-Traumatic Stress Disorder symptoms among individuals recently released from prison. J Urban Health. 2018 Apr; 95(2): 141-8.
Maradiaga JA, Nahvi S, Cunningham CO, Sanchez J, Fox AD. “I kicked the hard way. I got incarcerated.” Withdrawal from methadone during incarceration and subsequent aversion to medication assisted treatments. J Subst Abuse Treat. 2016 Mar; 62: 49-54.
Gonzalez CM, Fox AD, Marantz PR. The evolution of an elective in health disparities and advocacy: description of instructional strategies and program evaluation. Acad Med. 2015 Dec; 90(12): 1636-40.